S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:CVAC

CureVac (CVAC) Stock Forecast, Price & News

$18.73
-0.68 (-3.50%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$18.64
$20.06
50-Day Range
$14.70
$19.92
52-Week Range
$14.20
$125.66
Volume
564,414 shs
Average Volume
590,825 shs
Market Capitalization
$3.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
3.54
30 days | 90 days | 365 days | Advanced Chart
Receive CVAC News and Ratings via Email

Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter.

CureVac logo

About CureVac

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Headlines

CureVac (NASDAQ:CVAC) Shares Gap Up to $15.66
CureVac (CVAC) Q1 2022 Earnings Call Transcript
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CVAC
Employees
455
Year Founded
N/A

Sales & Book Value

Annual Sales
$115.57 million
Book Value
$4.13 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$3.50 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/29/2020
Today
5/22/2022
Next Earnings (Estimated)
7/28/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.38 out of 5 stars

Medical Sector

1095th out of 1,416 stocks

Pharmaceutical Preparations Industry

545th out of 677 stocks

Analyst Opinion: 3.1Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













CureVac (NASDAQ:CVAC) Frequently Asked Questions

Is CureVac a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CureVac in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CureVac stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVAC, but not buy additional shares or sell existing shares.
View analyst ratings for CureVac
or view top-rated stocks.

When is CureVac's next earnings date?

CureVac is scheduled to release its next quarterly earnings announcement on Thursday, July 28th 2022.
View our earnings forecast for CureVac
.

How were CureVac's earnings last quarter?

CureVac (NASDAQ:CVAC) posted its quarterly earnings results on Sunday, November, 29th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($54.37) by $54.13.
View CureVac's earnings history
.

What price target have analysts set for CVAC?

6 brokerages have issued twelve-month price objectives for CureVac's stock. Their forecasts range from $20.00 to $123.00. On average, they anticipate CureVac's stock price to reach $53.75 in the next year. This suggests a possible upside of 187.0% from the stock's current price.
View analysts' price targets for CureVac
or view top-rated stocks among Wall Street analysts.

Who are CureVac's key executives?
CureVac's management team includes the following people:
  • Dr. Franz-Werner Haas L.L.M., LLD, Ph.D., LL.M., CEO & Member of Management Board (Age 52, Pay $652.14k)
  • Mr. Pierre Kemula B.Sc., MD, CFO & Member of Management Board (Age 47, Pay $634.39k)
  • Dr. Igor Splawski M.Sc., Ph.D., Chief Scientific Officer & Member of Management Board (Age 53, Pay $427.61k)
  • Dr. Antony Blanc Ph.D., MD, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board (Age 52, Pay $386.73k)
  • Dr. Klaus Edvardsen M.D., Ph.D., Chief Devel. Officer & Member of Management Board
  • Mr. Malte Greune Ph.D., COO & Member of Management Board
  • Dr. Sarah Fakih, VP Corp. Communications & Investor Relations
  • Mr. Thorsten Schuller, Head of Corp. Communications
  • Slavica Stevanovic-Heck, Head of HR
  • Dr. Patrick Baumhof, Sr. VP of Technology
What other stocks do shareholders of CureVac own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CureVac investors own include Moderna (MRNA), Tesla (TSLA), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Pfizer (PFE), AstraZeneca (AZN), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and NIO (NIO).

When did CureVac IPO?

(CVAC) raised $200 million in an initial public offering on Friday, August 14th 2020. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers.

What is CureVac's stock symbol?

CureVac trades on the NASDAQ under the ticker symbol "CVAC."

Who are CureVac's major shareholders?

CureVac's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (2.09%), BlackRock Inc. (1.02%), State Street Corp (0.34%), Goldman Sachs Group Inc. (0.15%), Capital Fund Management S.A. (0.12%) and Group One Trading L.P. (0.00%).

Which institutional investors are selling CureVac stock?

CVAC stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, HAP Trading LLC, Goldman Sachs Group Inc., Group One Trading L.P., Cutler Group LP, Baillie Gifford & Co., ProShare Advisors LLC, and Vanguard Group Inc..

Which institutional investors are buying CureVac stock?

CVAC stock was purchased by a variety of institutional investors in the last quarter, including Capital Fund Management S.A., BlackRock Inc., Citigroup Inc., Invesco Ltd., Martingale Asset Management L P, State Street Corp, Healthcare of Ontario Pension Plan Trust Fund, and Dynamic Technology Lab Private Ltd.

How do I buy shares of CureVac?

Shares of CVAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CureVac's stock price today?

One share of CVAC stock can currently be purchased for approximately $18.73.

How much money does CureVac make?

CureVac has a market capitalization of $3.50 billion and generates $115.57 million in revenue each year.

How many employees does CureVac have?

CureVac employs 455 workers across the globe.

What is CureVac's official website?

The official website for CureVac is www.curevac.com.

How can I contact CureVac?

CureVac's mailing address is PAUL-EHRLICH-STRABE 15 TUBINGEN, BADEN-WURTTEMBERG 2M, 72076. The company can be reached via phone at 49-70-71988-30, via email at [email protected], or via fax at 49-7071-9883.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.